Empasug 25mg

Description:

• Empasug 25mg offers an intensified dose of empagliflozin (25 mg) for patients requiring stronger glycemic control. This once-daily SGLT2 inhibitor is recommended for adults with T2DM and offers added cardiovascular and renal benefits in patients with co-existing heart failure or chronic kidney disease (CKD).
• As a reliable empagliflozin 25mg tablets manufacturer, we ensure each tablet delivers clinically validated performance with consistent formulation quality.
• This product is widely trusted by diabetes medicine distributors for its effectiveness in managing high-risk diabetic cases.
• In addition, we are one of the leading empagliflozin 25mg tablets exporters, meeting global demand with a strong commitment to regulatory compliance.

Key Features:

• Enhanced HbA1c control for patients not achieving targets on lower doses
• Reduces hospitalization for heart failure and CV mortality
• Slows CKD progression by preserving kidney function
• Encourages urinary glucose excretion, improving insulin resistance
• Convenient oral therapy with minimal risk of hypoglycemia

Usage Guidelines:

• Administer once daily, with or without meals
• Appropriate as a step-up therapy from Empasug 10mg
• Requires baseline assessment of kidney function

Safety Profile:

• Common adverse effects include increased urination, genital infections
• Not suitable for patients with severe renal impairment
• Observe for hypovolemia, ketoacidosis, and urinary tract infections

Uses / Indications: Type 2 diabetes mellitus (T2DM) to improve blood sugar control, Heart failure to reduce cardiovascular death and hospitalization, Chronic kidney disease (CKD) to slow progression and lower CV risk.